In another major setback for abortion care in the US, a US court has issued an order restricting the distribution of ...

A cannabis-derived drug developed by Germany's Vertanical has shown efficacy in phase 3 as a treatment for chronic pain, offering the prospect of an alternative to opioid drugs that carry the risk of ...

Novo Nordisk has launched a direct-to-consumer (DTC) option for uninsured or under-insured people wanting to access its GLP-1 agonist weight-loss drug Wegovy, cutting the drug's price in half to $499 ...

Armed with positive results in two phase 3 trials, Takeda intends to file for approval of its oral psoriasis therapy zasocitinib in the US and other countries next year, with Bristol Myers Squibb's ...

GSK just hit one of its main objectives for 2025 after getting FDA approval of anti-IL-5 antibody Nucala as a treatment for chronic obstructive pulmonary disease (COPD). Nucala (mepolizumab) has been ...

Isomorphic Labs has raised a whopping $600 million to refine its artificial intelligence-powered drug discovery engine, advance its pipeline, and expand its headcount in its first external funding ...

Positive mid-stage results with Apogee Therapeutics' IL-13 inhibitor APG777 in atopic dermatitis have driven the company's shares up around 20%, as it prepares for a phase 3 programme. The 16-week ...

Novartis has claimed a first-in-class regulatory approval in the US for oral BTK inhibitor remibrutinib as a second-line treatment for chronic spontaneous urticaria (CSU), also known as chronic hives.

Almost 30,000 people in England with chronic obstructive pulmonary disease (COPD) could soon have access to a biologic treatment, Sanofi and Regeneron's Dupixent, after it was recommended for use by ...

Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a cancer therapy being developed by Scorpion Therapeutics in a third major transaction announced on the first day of the JP Morgan ...

NHS patients with type 2 diabetes (T2D) in England will get earlier access to SGLT-2 inhibitors, now that generics of one of the main drugs in the class – AstraZeneca's Forxiga – are available. Final ...

Viatris (formerly Mylan) has become the first drugmaker to win full FDA approval for a generic version of AstraZeneca's top-selling respiratory drug Symbicort, although launch plans remain uncertain ...